

# Afschin Gandjour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4436799/publications.pdf>

Version: 2024-02-01

113  
papers

1,400  
citations

361045

20  
h-index

433756

31  
g-index

121  
all docs

121  
docs citations

121  
times ranked

1604  
citing authors

#	ARTICLE	IF	CITATIONS
1	Threshold Volumes Associated With Higher Survival in Health Care. <i>Medical Care</i> , 2003, 41, 1129-1141.	1.1	103
2	Costs of dialysis—a regional population-based analysis. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1647-1652.	0.4	66
3	Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1441-1456.	2.2	62
4	Does prevention save costs?. <i>Journal of Health Economics</i> , 2005, 24, 715-724.	1.3	48
5	Theoretical Foundation of Patient v. Population Preferences in Calculating QALYs. <i>Medical Decision Making</i> , 2010, 30, E57-E63.	1.2	41
6	Review of Quality-of-Life Evaluations in Patients with Angina Pectoris. <i>Pharmacoeconomics</i> , 1999, 16, 141-152.	1.7	37
7	An Evidence-Based Evaluation of Quality and Efficiency Indicators. <i>Quality Management in Health Care</i> , 2002, 10, 41-52.	0.4	36
8	Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. <i>Value in Health</i> , 2018, 21, 525-531.	0.1	32
9	A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. <i>Health Policy</i> , 2007, 83, 257-267.	1.4	31
10	Consumption costs and earnings during added years of life - a reply to Nyman. <i>Health Economics (United Kingdom)</i> , 2006, 15, 315-317.	0.8	30
11	Costs of patients with chronic kidney disease in Germany. <i>PLoS ONE</i> , 2020, 15, e0231375.	1.1	30
12	How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 181-190.	1.0	29
13	When Is It Worth Introducing a Quality Improvement Program? A Mathematical Model. <i>Medical Decision Making</i> , 2003, 23, 518-525.	1.2	28
14	Cost-Effectiveness Analysis of Different Screening Procedures for Type 2 Diabetes: The KORA Survey 2000. <i>Diabetes Care</i> , 2004, 27, 2120-2128.	4.3	28
15	Nephron overload as a therapeutic target to maximize kidney lifespan. <i>Nature Reviews Nephrology</i> , 2022, 18, 171-183.	4.1	28
16	Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women. <i>Value in Health</i> , 2009, 12, 1106-1117.	0.1	26
17	Mutual dependency between capabilities and functionings in Amartya Sen's capability approach. <i>Social Choice and Welfare</i> , 2008, 31, 345-350.	0.4	25
18	Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany. <i>Pharmacoeconomics</i> , 2018, 36, 1285-1296.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. <i>BMC Health Services Research</i> , 2020, 20, 343.	0.9	24
20	Utilitarian Theories Reconsidered: Common Misconceptions, More Recent Developments, and Health Policy Implications. <i>Health Care Analysis</i> , 2003, 11, 229-244.	1.4	23
21	European Comparison of Costs and Quality in the Treatment of Acute Back Pain. <i>Spine</i> , 2005, 30, 969-975.	1.0	23
22	Germany's Decision Rule for Setting Ceiling Prices of Drugs. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 65-71.	1.0	22
23	Cost-Effectiveness of Different Strategies for Selecting and Treating Individuals at Increased Risk of Osteoporosis or Osteopenia: A Systematic Review. <i>Value in Health</i> , 2012, 15, 284-298.	0.1	21
24	The Practice-Makes-Perfect Hypothesis in the Context of Other Production Concepts in Health Care. <i>American Journal of Medical Quality</i> , 2003, 18, 171-175.	0.2	20
25	Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model. <i>PLoS ONE</i> , 2011, 6, e26139.	1.1	20
26	Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 647-659.	1.0	19
27	Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany. <i>Value in Health</i> , 2008, 11, 1088-1095.	0.1	18
28	Cost-Effectiveness of Implantable Defibrillators after Myocardial Infarction Based on 8-Year Follow-Up Data (MADIT II). <i>Value in Health</i> , 2011, 14, 812-817.	0.1	18
29	Direct Costs of Care in Germany for Children and Adolescents with Diabetes Mellitus in the Early Course After Onset. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2004, 17, 1551-9.	0.4	16
30	Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries. <i>Health Care Management Science</i> , 2006, 9, 359-369.	1.5	15
31	Economic evaluation of Sinfrontal® in the treatment of acute maxillary sinusitis in adults. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 181-191.	1.0	15
32	A new prize system for drug innovation. <i>Health Policy</i> , 2011, 102, 170-177.	1.4	15
33	Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 171-179.	0.7	15
34	The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. <i>Quarterly Review of Economics and Finance</i> , 2022, 84, 502-509.	1.5	15
35	Predictors of negotiated prices for new drugs in Germany. <i>European Journal of Health Economics</i> , 2020, 21, 1049-1057.	1.4	15
36	A Cost-Effectiveness Model of Screening Strategies for Amblyopia and Risk Factors and Its Application in a German Setting. <i>Optometry and Vision Science</i> , 2003, 80, 259-269.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Applied Health Economics and Health Policy, 2008, 6, 113-135.	1.0	13
38	Aging diseases do they prevent preventive health care from saving costs?. Health Economics (United Kingdom), 2000, 20, 13-20.	0.8	13
39	Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. International Journal of Technology Assessment in Health Care, 2010, 26, 62-70.	0.2	13
40	Empirical Validation of Patient versus Population Preferences in Calculating QALYs. Health Services Research, 2011, 46, 1562-1574.	1.0	13
41	Reference Pricing and Price Negotiations for Innovative New Drugs. Pharmacoeconomics, 2013, 31, 11-14.	1.7	13
42	How Much Does It Cost to Change the Behavior of Health Professionals? A Mathematical Model and an Application to Academic Detailing. Medical Decision Making, 2005, 25, 341-347.	1.2	12
43	A model to predict the cost-effectiveness of disease management programs. Health Economics (United Kingdom), 2011, 31, 11-14.	1.1	12
44	To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective. Kidney and Blood Pressure Research, 2013, 37, 168-180.	0.9	12
45	The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 403-409.	0.7	11
46	Presenting Germany's drug pricing rule as a cost-per-QALY rule. Health Care Management Science, 2012, 15, 103-107.	1.5	11
47	Is subjective well-being a useful parameter for allocating resources among public interventions?. Health Care Analysis, 2001, 9, 437-447.	1.4	8
48	Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria. European Journal of Cardio-thoracic Surgery, 2003, 24, 571-577.	0.6	8
49	Convergence of decision rules for value-based pricing of new innovative drugs. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 209-213.	0.7	8
50	Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule. International Journal of Health Planning and Management, 2015, 30, 395-402.	0.7	8
51	Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health Services Management Research, 2023, 36, 51-62.	1.0	8
52	Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland. International Clinical Psychopharmacology, 2004, 19, 201-208.	0.9	7
53	Incorporating feelings related to the uncertainty about future health in utility measurement. Health Economics (United Kingdom), 2008, 17, 1207-1213.	0.8	7
54	Investment in quality improvement: how to maximize the return. Health Economics (United Kingdom), 2010, 19, 31-42.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 297-305.	0.7	7
56	Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 123-129.	0.7	7
57	A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency. BMC Health Services Research, 2020, 20, 240.	0.9	7
58	Loss Aversion and Cost Effectiveness of Healthcare Programmes. Pharmacoeconomics, 2008, 26, 895-898.	1.7	6
59	Osteoporosis in German men: a cost-of-illness study. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 531-537.	0.7	6
60	Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two-step instrumental variables strategy. Health Economics (United Kingdom), 2019, 28, 101-122.	0.8	6
61	Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective. BMC Health Services Research, 2022, 22, 47.	0.9	6
62	The price of curing cancer. BMC Health Services Research, 2021, 21, 1328.	0.9	6
63	Inductive reasoning in medicine: lessons from Carl Gustav Hempel's "inductive-statistical" model. Journal of Evaluation in Clinical Practice, 2003, 9, 161-169.	0.9	5
64	The additive utility assumption of the QALY model revisited. Journal of Health Economics, 2010, 29, 325-328.	1.3	5
65	Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 215-223.	0.7	5
66	A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 341-347.	0.7	5
67	Technology assessment in dentistry: A comparison of the longevity and cost-effectiveness of inlays. International Journal of Technology Assessment in Health Care, 2005, 21, 319-325.	0.2	4
68	Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. Applied Health Economics and Health Policy, 2011, 9, 259-273.	1.0	4
69	Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction. Health Services Management Research, 2012, 25, 138-143.	1.0	4
70	Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach. Applied Health Economics and Health Policy, 2014, 12, 471-476.	1.0	4
71	Health care expenditures from living longer—how much do they matter. International Journal of Health Planning and Management, 2014, 29, 43-51.	0.7	4
72	Patient preferences: a Trojan horse for evidence-based medicine?. European Journal of Health Economics, 2018, 19, 167-172.	1.4	4

#	ARTICLE	IF	CITATIONS
73	Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 109-125.	1.0	4
74	Impact of Demographic Changes on Healthcare Expenditures and Funding in the EU. <i>Applied Health Economics and Health Policy</i> , 2005, 4, 1-4.	1.0	3
75	Protocol-driven costs in trial-based pharmacoeconomic analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 673-675.	0.7	3
76	Internal validation of models with several interventions. <i>European Journal of Health Economics</i> , 2013, 14, 901-909.	1.4	3
77	Considering productivity loss in cost-effectiveness analysis: a new approach. <i>European Journal of Health Economics</i> , 2014, 15, 787-790.	1.4	3
78	Welfare gains and losses caused by clinical practice guidelines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 27-33.	0.7	3
79	Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing. <i>International Journal of Public Sector Management</i> , 2014, 27, 501-511.	1.2	3
80	Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results. <i>PLoS ONE</i> , 2020, 15, e0236543.	1.1	3
81	Value-based pricing of a COVID-19 vaccine. <i>Quarterly Review of Economics and Finance</i> , 2022, 84, 1-8.	1.5	3
82	Is it Rational to Pursue Utilitarianism?. <i>Ethical Perspectives</i> , 2007, 14, 139-158.	0.1	2
83	A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG). <i>Health Services Management Research</i> , 2013, 26, 103-109.	1.0	2
84	Comment on: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines". <i>Pharmacoeconomics</i> , 2014, 32, 1245-1246.	1.7	2
85	Capturing Disutility from Waiting Time. <i>Pharmacoeconomics</i> , 2014, 32, 423-424.	1.7	2
86	A model to optimize investments in health technologies, quality of care and research. <i>Applied Economics</i> , 2015, 47, 2031-2039.	1.2	2
87	Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". <i>Pharmacoeconomics</i> , 2015, 33, 981-982.	1.7	2
88	Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation". <i>Pharmacoeconomics</i> , 2017, 35, 603-604.	1.7	2
89	Deterministic Sensitivity Analysis Under Ignorance. <i>Pharmacoeconomics</i> , 2021, 39, 1197-1198.	1.7	2
90	Financial Incentives in the Path to Recovery from the COVID-19 Pandemic. <i>Applied Health Economics and Health Policy</i> , 2021, 20, 5.	1.0	2

#	ARTICLE	IF	CITATIONS
91	Pharmaceutical spending and early-stage innovation in EU countries. <i>Industry and Innovation</i> , 2022, 29, 1141-1170.	1.7	2
92	An evidence-based disease-management program for patients with diabetic nephropathy. <i>Journal of Nephrology</i> , 2003, 16, 500-10.	0.9	2
93	Vaccination Mandates, Physically Forced Vaccination, and Rationing in the Intensive Care Unit: Searching for Ethical Coherence in the COVID-19 Pandemic. <i>American Journal of Bioethics</i> , 2022, 22, 11-14.	0.5	2
94	Simplifying rules for optimal allocation of preventive care resources. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 231-235.	0.7	1
95	Validation of Models That Estimate the Cost-Effectiveness of Improving Patient Adherence. <i>Value in Health</i> , 2013, 16, 1170-1171.	0.1	1
96	Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries. <i>European Journal of Health Economics</i> , 2015, 16, 907-907.	1.4	1
97	Comment on: "The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review" <i>Applied Health Economics and Health Policy</i> , 2016, 14, 729-730.	1.0	1
98	Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 507-509.	1.0	1
99	Comment on: "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011" <i>Applied Health Economics and Health Policy</i> , 2016, 14, 241-241.	1.0	1
100	Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation. <i>Health Economics (United Kingdom)</i> , 2016, 25, 249-256.	0.8	1
101	Prioritizing health services research: an economic perspective. <i>European Journal of Health Economics</i> , 2016, 17, 375-377.	1.4	1
102	Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany" <i>European Journal of Health Economics</i> , 2018, 19, 471-472.	1.4	1
103	Underuse of innovative medicines in Germany: A justification for government intervention?. <i>Health Policy</i> , 2018, 122, 1283-1286.	1.4	1
104	What drives US competitiveness in mathematics and science?. <i>Educational Studies</i> , 2008, 34, 269-270.	1.4	0
105	Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 43-46.	0.7	0
106	Comment on: "Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care" <i>European Journal of Health Economics</i> , 2015, 16, 451-452.	1.4	0
107	FP396 Costs of patients with Chronic Kidney Disease in Germany. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	0
108	Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly. <i>European Journal of Health Economics</i> , 2020, 21, 663-664.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Defining Comparators According to IQWiG's Efficiency-Frontier Method. Value in Health, 2020, 23, 674-675.	0.1	0
110	A parsimonious model to validate cost-effectiveness analyses on preventive health care. BMC Health Services Research, 2021, 21, 1213.	0.9	0
111	Optimal Sample Size Calculation for Clinical Research under a Budget Constraint. Medical Decision Making, 2022, 42, 417-418.	1.2	0
112	Demonstrating the value of cancer biomarkers at the population level. European Journal of Health Economics, 2022, , .	1.4	0
113	Comment on "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective". Pharmacoeconomics, 0, , .	1.7	0